Renalytix Plc (LON:RENX – Get Free Report)’s share price was up 13% on Thursday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.48 ($0.11). Approximately 182,612 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 458,737 shares. The stock had previously closed at GBX 7.50 ($0.10).
Renalytix Price Performance
The company has a 50 day moving average of GBX 9.56 and a two-hundred day moving average of GBX 15.80. The firm has a market cap of £14.06 million, a P/E ratio of -33.23 and a beta of 2.10. The company has a quick ratio of 2.42, a current ratio of 0.53 and a debt-to-equity ratio of 173.95.
Insider Buying and Selling at Renalytix
In other Renalytix news, insider Christopher H. B. Mills sold 83,696 shares of Renalytix stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of GBX 8 ($0.10), for a total value of £6,695.68 ($8,693.43). 35.74% of the stock is owned by corporate insiders.
Renalytix Company Profile
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Featured Articles
- Five stocks we like better than Renalytix
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Upcoming IPO Stock Lockup Period, Explained
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.